Cardiac benefits of mineralocorticoid receptor inhibition in renal failure.
Graf
Kristof
K
Hucko
Thomas
T
Stawowy
Philipp
P
D000450:Aldosterone / Q000378:metabolism; D000818:Animals; D015331:Cohort Studies; D004195:Disease Models, Animal; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000209:etiology / Q000517:prevention & control*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D051379:Mice; D000451:Mineralocorticoid Receptor Antagonists; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D018384:Oxidative Stress; D051381:Rats; D013148:Spironolactone / Q000008:administration & dosage*; D016896:Treatment Outcome
D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000450:Aldosterone; D052247:Nitric Oxide Synthase Type II